Most insurance plans do not cover enclomiphene. The medication is compounded, it has never received FDA approval for any indication, and most formularies exclude compounded drugs entirely. Men prescribed enclomiphene for secondary hypogonadism typically pay $50-$150 per month out of pocket, depending on the compounding pharmacy, dose, and geographic location. That price usually covers the medication alone, not the lab work or clinical evaluations required alongside it.

Enclomiphene citrate is a selective estrogen receptor modulator (SERM) that works by acting on the HPG axis to stimulate the body's own testosterone production, rather than replacing testosterone from an outside source. A 2025 systematic review of 10 randomized controlled trials found that clomiphene or enclomiphene raised total testosterone by a mean of 273.76 ng/dL compared to placebo, though heterogeneity across studies was high (I² = 89%) and individual responses vary. The review also found evidence suggesting preservation of spermatogenesis (Hohl et al., 2025). That potential for fertility preservation is one reason clinicians at telehealth-based providers consider it for men with secondary hypogonadism who plan to have children.

This article focuses on cost and insurance coverage, not fertility protocols or adjunct therapies. It addresses one question: what does enclomiphene actually cost, and who pays for it?

Why Don't Most Insurance Plans Cover Enclomiphene?

Insurance coverage for enclomiphene is rare because the drug sits outside the standard formulary system. Enclomiphene never completed the FDA approval process. Repros Therapeutics developed it under the brand name Androxal but received Complete Response Letters from the FDA citing study design and entry criteria issues. Development was discontinued around 2021. Without an approved New Drug Application (NDA), enclomiphene has no National Drug Code (NDC) entry in most pharmacy systems, which means insurers have no standard billing pathway for it.

Compounded medications, by definition, are not FDA-approved for safety, efficacy, or manufacturing quality (FDA, 2024). They're prepared by 503A pharmacies on a patient-specific basis with a valid prescription. Most commercial insurance plans, Medicare Part D, and Medicaid programs exclude compounded drugs from covered formularies. Even plans that cover testosterone replacement therapy (TRT), an FDA-approved treatment for diagnosed hypogonadism, typically won't extend that coverage to a compounded alternative like enclomiphene.

There are narrow exceptions. Some plans will process a compounded medication claim if the prescriber submits documentation of medical necessity, typically lab-confirmed low testosterone plus a clinical reason that FDA-approved options aren't appropriate (such as fertility preservation). But prior authorization requirements, appeals, and claim denials make this pathway unreliable. Most clients end up paying out of pocket.

How Much Does Enclomiphene Cost Without Insurance?

Out-of-pocket enclomiphene cost ranges from $50 to $150 per month at most compounding pharmacies. The price depends on several variables.

Dose and formulation. Common compounding doses include 12.5 mg and 25 mg, though prescribing is individualized and off-label. Higher doses or custom formulations (capsules vs. tablets) can push the monthly cost toward the upper end of that range.

Compounding pharmacy pricing. 503A pharmacies set their own prices. A pharmacy in a major metropolitan area may charge more than one in a smaller market. Some telehealth providers bundle medication, shipping, and provider consultations into a single monthly cost, while others bill each line item separately.

Lab work and consultations. The medication cost alone doesn't capture the full expense. Clinical guidelines from the AUA suggest a testosterone deficiency threshold as a reasonable cut-off, confirmed on two separate early-morning draws along with consistent symptoms (Mulhall et al., 2018). Follow-up lab panels ordered by the prescribing clinician add $100-$400 or more, depending on the provider and monitoring schedule.

HSA and FSA eligibility. Enclomiphene prescribed by a licensed clinician for a diagnosed condition is generally eligible for Health Savings Account (HSA) and Flexible Spending Account (FSA) reimbursement. This effectively reduces the net cost by the patient's marginal tax rate. Direct-pay telehealth providers often accept HSA/FSA cards at checkout.

How Does Enclomiphene Cost Compare to TRT?

The cost comparison between enclomiphene and testosterone replacement therapy depends on whether the patient has insurance coverage for TRT and which formulation is prescribed.

Generic testosterone cypionate injections are often the least expensive TRT option, sometimes available for under $30 per month with a prescription. Topical gels and patches cost more, and implantable pellets can run over $500 per insertion. When a patient has insurance that covers TRT, the out-of-pocket cost after copays may be lower than paying cash for enclomiphene.

For men paying entirely out of pocket, enclomiphene and generic injectable testosterone fall into a similar price range. The clinical difference, not the price, is usually what drives the choice. Enclomiphene stimulates endogenous production and may preserve sperm parameters. Exogenous testosterone suppresses the HPG axis and can reduce sperm counts, sometimes to zero. The Endocrine Society's 2018 guideline recommends against starting testosterone therapy in clients planning fertility in the near term (Bhasin et al., 2018). The choice between these approaches depends on individual clinical factors, fertility plans, and a patient's discussion with their clinician.

Men weighing these options should discuss their fertility goals with a licensed clinician before starting either treatment.

What Factors Drive the Price of Enclomiphene?

Several variables affect what a patient actually pays.

Geographic location. Compounding pharmacy pricing isn't standardized. Costs vary by state, by pharmacy, and even by the specific compounding process used. Clients in states with fewer 503A pharmacies may face higher prices or longer shipping times.

Prescribing channel. An in-person endocrinologist visit may involve separate charges for the consultation, lab orders, and medication. Telehealth providers sometimes bundle these into a single monthly fee, which can simplify budgeting but may cost more than purchasing each component separately. Clients should ask exactly what's included before committing.

Treatment duration. Enclomiphene is typically prescribed on an ongoing basis for as long as the clinical need exists. Unlike a short course of antibiotics, this is a recurring monthly expense. Providers who offer longer prepaid plans (3, 6, or 12 months) sometimes discount the per-month rate.

Monitoring requirements. Responsible prescribing includes periodic lab work as directed by the prescribing clinician. No formal monitoring guideline exists for enclomiphene specifically, though providers often follow principles similar to those used for testosterone therapy (Bhasin et al., 2018). These labs cost money, and skipping them isn't safe.

Is Enclomiphene Safe?

Available clinical trial data suggest enclomiphene is tolerated by most participants in short-term studies, though trials have been small and long-term safety data are limited. Reported side effects include headaches, nausea, hot flashes, and elevated estrogen levels. Some clients experience visual disturbances, a known class effect of SERMs. Men with a history of venous thromboembolism or certain cardiac conditions should discuss these risks with their clinician before starting enclomiphene.

Enclomiphene is the trans-isomer of clomiphene citrate (marketed as Clomid for ovulatory dysfunction in women). Research comparing the two has found that enclomiphene may produce fewer estrogenic side effects (such as mood changes and gynecomastia) because it lacks the zuclomiphene isomer responsible for prolonged estrogen receptor activation. But "fewer side effects than clomiphene" isn't the same as "no side effects." Regular lab monitoring, as directed by the prescribing clinician, is recommended.

No large-scale cardiovascular safety trial equivalent to TRAVERSE exists for enclomiphene. The TRAVERSE trial (5,246 men, published in the New England Journal of Medicine) established that testosterone replacement was neutral on the primary cardiac endpoint but associated with higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury (Lincoff et al., 2023). For enclomiphene, no comparable data exist. Individual results vary, and all prescribing decisions should be made by a licensed clinician based on lab confirmation and clinical evaluation.

How to Get an Enclomiphene Prescription

Enclomiphene requires a prescription from a licensed clinician after a proper diagnostic workup. That process includes blood work confirming low testosterone on two separate early-morning draws, plus documented symptoms consistent with testosterone deficiency.

Telehealth platforms have expanded access to enclomiphene prescriptions for men in states where the prescribing clinician is licensed. The DEA's temporary telemedicine flexibility, extended through December 31, 2026, permits prescribing certain medications (including those related to hormone therapy) via telehealth without an initial in-person visit, though state-specific rules apply and this flexibility is not permanent.

Clients should confirm that any telehealth provider they work with uses a licensed 503A compounding pharmacy, includes lab monitoring as part of the protocol, and assigns a named credentialed clinician to their case. Prescription required after evaluation.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Does insurance cover enclomiphene for low testosterone? 

Most insurance plans do not cover enclomiphene because it is a compounded medication without FDA approval. Compounded drugs are excluded from standard formularies. Some plans may process a claim with documentation of medical necessity, but denials are common and most patients pay out of pocket.

How much does enclomiphene cost per month? 

Enclomiphene typically costs $50-$150 per month from a compounding pharmacy, depending on dose, formulation, and location. That figure covers the medication only. Lab work, consultations, and follow-up monitoring add to total treatment costs and may range from $100 to $400 per panel.

Is enclomiphene cheaper than testosterone replacement therapy? 

It depends on the TRT formulation and insurance status. Generic testosterone cypionate injections can cost as little as $30 per month, making them less expensive than enclomiphene in some cases. Topical gels and patches run $200-$500 monthly without insurance. For uninsured patients, enclomiphene and generic injectable TRT fall into a similar price range.

Can HSA or FSA funds pay for enclomiphene? 

Enclomiphene prescribed by a licensed clinician for a diagnosed medical condition is generally eligible for HSA and FSA reimbursement. This allows patients to use pre-tax dollars, reducing the effective cost by their marginal tax rate.

Why is enclomiphene not FDA-approved? 

Repros Therapeutics attempted to gain FDA approval for enclomiphene under the brand name Androxal but received Complete Response Letters citing study design issues, entry criteria concerns, and requests for additional data. Development was discontinued around 2021. Enclomiphene remains available only as a compounded medication.

What monitoring is needed while taking enclomiphene? 

Patients on enclomiphene should have baseline and follow-up lab work as directed by their prescribing clinician. No formal monitoring guideline exists specifically for enclomiphene, though providers typically follow principles similar to those used for testosterone therapy. Monitoring frequency depends on individual response and risk factors.

Is enclomiphene the same as Clomid? 

Not exactly. Enclomiphene is the trans-isomer of clomiphene citrate, the active ingredient in Clomid. Clomid contains both enclomiphene and zuclomiphene. Research suggests enclomiphene may produce fewer estrogenic side effects (such as gynecomastia and mood changes) because it lacks the zuclomiphene isomer. Clomid is FDA-approved for ovulatory dysfunction in women but is used off-label in men.

References

• Hohl A, et al. Arch Endocrinol Metab. 2025;69(5):e250093

• AUA. J Urol. 2018;200:423-432

• Bhasin S, et al. J Clin Endocrinol Metab. 2018;103(5):1715-1744

• FDA. Human Drug Compounding. 2024

• Lincoff AM, et al. N Engl J Med. 2023;389:107-118